News und Analysen

Income investors love high dividend yields. Unfortunately, those yields often come with unacceptable trade-offs in the form of significant risk and/or low overall growth prospects. That's not always

Investors in AngioDynamics (NASDAQ: ANGO), inventor of the innovative Nanoknife device for electrocuting cancer cells, got an unpleasant shock of their own on Friday morning. Though the company

Investors seeking stocks that can produce dramatic gains in 2024 can find what they're looking for in the biopharmaceutical industry. Clinical-trial results that these two companies are expected to

It's never easy to make a list of the "best" of anything, much less stocks to buy. People invest in equities based on various factors that are different from one person to the next and will

Turning $1,000 into $2,400 in five years is no easy feat -- it requires a compound annual growth rate (CAGR) of 19.1%. However, both Regeneron (NASDAQ: REGN) and Moderna (NASDAQ: MRNA) have been

Niche tech stock Pure Storage (NYSE: PSTG) had a fine Wednesday on the market, with its shares racing nearly 5% higher in value. By contrast, the S&P 500 index slumped by 0.8%. Investors were

Abbott Laboratories (NYSE: ABT) is a longtime leader in the healthcare industry. The medical device specialist has been around for decades, delivering solid returns to its loyal shareholders

AbbVie (NYSE: ABBV) is a top pharmaceutical company with a broad mix of products in its portfolio. It also pays an attractive dividend, which yields 4% -- that's more than twice the S&P 500 average

Big pharma is facing another round of major patent expirations. Before the decade's end, Bristol Myers Squibb (BMS) will lose exclusivity for the megablockbuster blood thinner Eliquis as well as its

Growth stocks get the designation because they have the potential to generate life-changing gains for investors. Some even do so in a relatively short time frame. Finding proper growth stocks

There are many ways to grow one's wealth over a decade, but few are as accessible as investing in stocks. Even with a relatively modest sum, picking the right investments and letting time and

Dividends are nice. But do you know what's even nicer? Fast-growing dividends. That's especially true with inflation eroding the purchasing power of your money.

The good news for income investors is

Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years. The company is now the most valuable healthcare company in the world, with a valuation of around $550

No person knows for sure what the future will hold for stocks in the new year. However, it can be fun to attempt to predict what might happen.

Three Fool.com contributors have done just that. Here's

Inflation is arguably the top economic story of the last couple of years. Indeed, consumer purchasing power is down 16% since the beginning of 2020. That means $1,500 would only buy $1,260 worth of

With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex

Dividend stocks can be incredible investments. They've historically outperformed the market over the long term. The best returns have come from companies that routinely increase their dividends.

Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task.

Three Motley Fool contributors think

While investors may be hoping for a full-throttled bull market to appear in the new year, some great companies with long-term competitive advantages and robust financials remain at reasonable

Shares of Coherus BioSciences (NASDAQ: CHRS) are up 19.7% as of 3:20 p.m. ET Thursday after the U.S. Food and Drug Administration (FDA) approved Udenyca OnBody, the company's on-body injection

Biotech stocks are often challenging for investors to evaluate without having a full scientific context, and Sarepta Therapeutics (NASDAQ: SRPT) is no exception. With multiple successful products on

You might call it a "Pfizzle."

In late 2021, Pfizer (NYSE: PFE) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine.

It followed

Sometimes a company has a mixture of proven performance and upcoming catalysts that make the idea of buying it hand-over-fist practically irresistible. And that's exactly what Vertex Pharmaceuticals

Drug patents don't last forever, so pharmaceutical companies are constantly looking for the next big treatment to broaden their total portfolio of offerings.

When it was clear a few years ago that

Small-cap stocks have been under pressure ever since the Federal Reserve started hiking interest rates in the first quarter of 2022. As a result, scores of companies in this category sport